-
Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety
Tuesday, June 1, 2021 - 8:15am | 313Read More...Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after more frequent dosing intervals were associated with higher rates of intraocular inflammation. The MERLIN study and the...
-
Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study
Thursday, May 6, 2021 - 12:28pm | 275Read More...Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases. The data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021...
-
OHR Pharmaceutical Gains 7% Following Agreement With FDA
Tuesday, March 29, 2016 - 9:05am | 190Read More...Shares of OHR Pharmaceutical Inc (NASDAQ: OHRP), a nano-cap pharmaceutical company that focuses on the treatment of ocular diseases, spiked higher by more than 7 percent early Tuesday morning. OHR Pharmaceutical announced it has reached an agreement on the Special Protocol Assessment (SPA) with the...
